FLX-787-ODT (orally disintegrating tablet) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 10 | Charcot-Marie-Tooth disease | 1 |
10. Charcot-Marie-Tooth disease
Clinical trials : 41 / Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03254199 (ClinicalTrials.gov) | October 16, 2017 | 16/8/2017 | A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps. | A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease | Charcot-Marie-Tooth Disease | Drug: FLX-787-ODT (orally disintegrating tablet);Drug: Placebo ODT | Flex Pharma, Inc. | NULL | Terminated | 18 Years | N/A | All | 27 | Phase 2 | United States |